Navigation Links
Chemical signature of manic depression discovered by scientists
Date:2/5/2008

People with manic depression have a distinct chemical signature in their brains, according to a new study. The research, published today in the journal Molecular Psychiatry, may also indicate how the mood stabilisers used to treat the disorder counteract the changes in the brain that it appears to cause.

Manic depression, which is also known as bipolar disorder, is a debilitating psychiatric condition characterised by alternating mania and depression, affecting about one in every hundred people worldwide. Although it is known that the condition can be treated relatively effectively using the mood-stabilising drugs lithium and valproic acid, the reasons why these treatments work are poorly understood.

The authors of the new study, from Imperial College London, the University of Cambridge, and the National Institutes of Mental Health in the US, hope that their research will enable a better understanding of the condition and of how it can be treated.

The researchers compared postmortem brain tissue samples of people with manic depression with those of age and gender matched controls. The samples were taken from the dorsolateral prefrontal cortex, which controls the processes involved in higher cognitive functioning. The researchers analysed these samples using Nuclear Magnetic Resonance spectroscopy and found that people with manic depression had different concentrations of chemicals in this area of the brain than those without.

The researchers also used rat models to see the effects of lithium and valproic acid on the metabolite makeup of non-bipolar brain tissue. They found that these drugs caused the opposite chemical changes to those seen in the bipolar brain tissue samples. Chemicals that were increased in the bipolar brain tissue were decreased in rats given the mood stabilising drugs, and vice versa.

The researchers findings lead them to believe that an upset in the balance of different neurotransmitters known as excitatory and inhibitory neurotransmitters, which are involved in sending signals in the brain, may be central to the disorder. The study also suggests that lithium and valproic acid work by restoring the balance of these neurotransmitters in the brain.

Levels of glutamate, an amino acid which acts as a neurotransmitter in the central nervous system, were increased in post mortem bipolar brain but glutamate / glutamine ratios were decreased following valproate treatment. Levels of another neurotransmitter, gamma-aminobutyric acid, were increased after lithium treatment and decreased in the bipolar brain. Both creatine and myo-inositol were increased in the post-mortem brain but depleted with the medications.

Dr Tsz Tsang, one of the authors of the study from the Department of Biomolecular Medicine at Imperial College London, said: By identifying a distinct biochemical profile in patients with bipolar disorder, our new research provides a valuable insight into the origins and causes of the disease. Moreover, the changes we see in peoples metabolic signatures may give a target for drug therapy, allowing us to see how effective a drug is at correcting these changes.

In this instance, we have already shown that the biochemical changes which valproic acid and lithium bring about in mammalian models represent almost a mirror image of the perturbations in bipolar disorder. This may provide a useful insight to the actions of these treatments and a basis for which to improve therapy in the future, added Dr Tsang.


'/>"/>
Contact: Abigail Smith
abigail.smith@imperial.ac.uk
44-020-759-46701
Imperial College London
Source:Eurekalert

Related medicine news :

1. Chemical chaperone could open door to treatment of neurological disorder
2. Chemical Linked to Reproductive Harm Is Getting Into Babies From Shampoo, Lotion and Powder, New Study Suggests
3. American Chemical Societys Weekly PressPac -- Jan. 30, 2008
4. Many Babies Exposed to Chemicals
5. Heating Plastic Bottles Releases Potentially Harmful Chemical
6. Hot liquids release potentially harmful chemicals in polycarbonate plastic bottles
7. American Chemical Societys weekly PressPac -- Jan. 23, 2008
8. From Research to Practice: Healthfitness, Eastman Chemical Company Case Study Demonstrates Real-World Health Gains and Productivity Savings
9. Herons persist in Chicago wetlands despite exposure to banned chemicals
10. Sleep chemical central to effectiveness of deep brain stimulation
11. Results promising for computational quantum chemical methods for drug development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Coast Dental Fort Stewart is celebrating its ... location in the Exchange Furniture Mall at 112 Vilseck Road in Fort Stewart. There ... TV. Plus attendees will have the opportunity to meet general dentists Thomas Richards, DDS, ...
(Date:4/29/2016)... Kansas City, Missouri (PRWEB) , ... April 29, 2016 , ... ... Unlike traditional crutches which put pressure on the armpits, the M+D Crutch evenly distributes ... less strain on their wrists and hands when using the crutches than with other ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Robert Mondavi, one of the ... Cosmetic dentistry is a fast-growing field as more patients are discovering the many different ... more about the options currently available to them and which ones might work for ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the market ... funding led by Eastside Partners, with participation from existing investor Martin Ventures. ... and accelerate its technology and product roadmap. , “Jvion is experiencing ...
(Date:4/29/2016)... ... 2016 , ... The infertility specialists at HRC Fertility/Orange County (HRC/OC) -- Dr. ... Potter -- are proud of the recent release of their 2014 in vitro fertilization ... published the latest verified data for 375 U.S. member clinics. *Preliminary data shows ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... -- Dr. Vivek Ahuja , ... Ste phen Schmidt Join ... cloud-based software solutions for life sciences, today announced key new leaders ... of insight to a growing business.  This will bolster the company,s ... Phillips joined ArisGlobal in the position of Vice President - ...
(Date:4/28/2016)... April 28, 2016 New ... 2016" is a report that provides an overview ... R&D pipelines by identifying new targets and MOAs ... Company Profiles discussed in this H1 2016 Osteoarthritis ... Srl, AbbVie Inc., Abiogen Pharma S.p.A., Ablynx NV, ...
(Date:4/27/2016)... 27, 2016 Elekta today announced ... will be the focal point of seven scientific presentations ... Society for Radiotherapy & Oncology, taking place April 29 ... state-of-the-art radiotherapy system and a high-field MRI scanner with ... the patient,s anatomy in real time. The MR-linac is ...
Breaking Medicine Technology: